Signal2026-08-06
ClinicalTrials.gov

[PHASE2] SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma

Part of

Molecular Profiling In Endocrine Neoplasms

Open primary sourceSee the whole picture